Tag: anti-prM

Jun 03, 2026

• ANA
• antinuclear-antibody
• dengue
• autoimmunity
• molecular-mimicry
• bystander-activation
• epitope-spreading
• post-dengue
• IIF
• HEp-2
• LIA
• prevalence
• healthy-population
• acute-phase
• IIFA
• FcγRIIa
• NS1
• MAS
• HLH
• macrophage-activation
• NS1-IgG-kinetics
• primary-infection
• PAIgG
• PAIgM
• ANA-negative
• polyreactive-IgM
• nuclear-antigen-consumption
• thrombocytopenia-bifurcation
• immune-complex
• anti-prM
• vaccine-design
• P311-330
• PDI
• epitope-mapping
• FcγRIIa-paradox
• anti-EC-isotype-shift
• dengue-mimickers
• false-positive-serology
• SLE-dengue-differential
• literature-review
• synthesis

Apr 19, 2026

• cross-reactivity
• ADE
• neutralisation
• IgG
• IgA
• IgM
• IgG3
• IgG4
• serotype
• E-protein
• NS1
• EDI-II
• EDIII
• flavivirus
• diagnostics
• vaccine
• longitudinal
• antibody-kinetics
• anti-prM
• prM
• structural-antibody
• anti-endothelial
• anti-platelet
• Vietnam
• infection-order

Apr 19, 2026

• secondary-infection
• ADE
• DHF
• DSS
• heterotypic
• cross-reactive-antibodies
• disease-severity
• thrombocytopenia
• PAIgG
• PAIgM
• immune-complex
• DHF-predictor
• anti-prM
• anti-endothelial
• IgG
• isotype-switch
• Vietnam

Apr 19, 2026

• serotype
• DENV-1
• epidemiology
• secondary-infection
• ADE
• Singapore
• Nicaragua
• antibody-kinetics
• anti-prM
• cross-reactivity
• NS1-levels
• viraemia

Apr 19, 2026

• serotype
• DENV-3
• Cuba
• displacement
• epidemic-dynamics
• CNS-invasion
• neuropathogenesis
• Singapore
• Taiwan
• Nicaragua
• anti-platelet
• IgM
• primary-infection
• antibody-kinetics
• autoantibody-cross-serotype
• anti-prM
• cross-reactivity

Apr 19, 2026

• Southeast-Asia
• regional
• endemic
• Thailand
• Singapore
• Philippines
• Vietnam
• Cambodia
• DENV-1
• DENV-2
• DENV-3
• DENV-4
• hyperendemic
• paediatric-dengue
• DHF
• autoimmunity
• PAIgG
• PAIgM
• thrombocytopenia
• anti-platelet
• anti-endothelial
• ADE
• anti-prM
• asymptomatic

Apr 18, 2026

• E-protein
• envelope-protein
• structural-protein
• receptor-binding
• vaccine-target
• fusion
• neutralising-antibody
• WGNGCG
• coagulation
• EDI-II
• EDIII
• cross-reactive
• longitudinal
• IgG-kinetics
• anti-prM
• structural-antibody-proportion

Apr 18, 2026

• serology
• IgM
• IgG
• ELISA
• diagnostics
• convalescent-phase
• secondary-infection
• Zika
• cross-reactivity
• MAC-ELISA
• anti-dengue-IgG
• anticardiolipin
• anti-prM
• research-ELISA
• India

Apr 17, 2026

• ADE
• immunopathogenesis
• FcR
• secondary-infection
• severe-dengue
• IGHG1
• plasmablast
• scRNA-seq
• IgG-affinity
• FcgRIIIA
• SPR
• anti-prM
• prM-cleavage
• monocyte
• vaccine-design
• ADE-window
• enhancement-titer
• Katzelnick

Apr 17, 2026

• vaccines
• CYD-TDV
• DENVax
• TAK-003
• TV003
• tetravalent
• live-attenuated
• subunit
• ADE
• seronegative
• phase-III
• correlates-of-protection
• anti-prM
• prM-design
• ADE-risk
• ADE-window
• enhancement-titer
• Katzelnick

Apr 17, 2026

• serotype
• DENV-2
• Asian-genotype
• virulence
• ADE
• secondary-infection
• Cuba
• CNS-invasion
• neuropathogenesis
• anti-platelet
• IgM
• autoantibody-cross-serotype
• anti-prM
• cross-reactivity
• NS3
• salivary-gland-replication

Apr 17, 2026

• serotype
• DENV-4
• Cuba
• epidemic
• autoantibody-cross-serotype
• anti-prM
• cross-reactivity

Apr 17, 2026

• Thailand
• Southeast-Asia
• DENFREE
• epidemiology
• cohort
• anti-prM
• monoclonal-antibody
• ADE

Apr 17, 2026

• serology
• neutralising-antibody
• PRNT
• gold-standard
• virus-isolation
• anti-prM
• neutralisation-ceiling

Apr 17, 2026

• anti-prM
• ADE
• cross-reactive-antibodies
• neutralisation
• monocyte
• dendritic-cell
• vaccine-design
• prM-cleavage
• monoclonal-antibody
• structural-antibody

Apr 17, 2026

• DHF-pathogenesis
• NS1
• ADE
• sfRNA
• T-cells
• complement
• NLRP3
• anti-prM
• OAS
• genome-variation
• IFN-suppression
• review

Apr 12, 2026

• molecular-mimicry
• NS1
• anti-prM
• coagulation
• platelets
• endothelial-cells
• DHF
• autoimmunity
• flavivirus
• hemorrhage
• Taiwan
• minireview